REVIEW

# Innovations in Oral Drug Bioavailability Enhancement Techniques

**Anup Sharma**

Department of Pharmacology
Delhi Institute of Pharmaceutical Sciences and
Research, New Delhi, India.

**Correspondence:**
Anup Sharma,
Department of Pharmacology
Delhi Institute of Pharmaceutical Sciences and
Research, New Delhi -110021, India.
E-mail: anoopniper@gmail.com

**How to cite this article:** Sharma A. Innovations in Oral Drug Bioavailability Enhancement Techniques Innov Pharm Planet (IP-Planet) 2020;08(1):1-4.

**Source of Support:** Nil.
**Conflicts of Interest:** None declared.

**Date of Submission:** 09-01-2020
**Date of Revision:** 11-02-2020
**Date of Acceptance:** 25-02-2020

## ABSTRACT

Oral drug administration is the most common and preferred route of drug delivery; however, achieving optimal bioavailability remains a major challenge due to factors like poor solubility, low intestinal permeability, and first-pass metabolism. Enhancing the bioavailability of oral drugs is crucial for improving therapeutic efficacy and reducing dose-related side effects. This review explores recent innovations in techniques aimed at enhancing oral drug bioavailability. Key strategies include physicochemical approaches such as particle size reduction, salt formation, and amorphous solid dispersions to improve solubility. Formulation-based techniques like lipid-based drug delivery systems, cyclodextrin complexation, and nanotechnology-based carriers (e.g., nanoparticles, liposomes) are discussed for improving drug dissolution and absorption. Biological and biopharmaceutical approaches, including enzyme inhibitors, permeability enhancers, prodrug design, and gastroprotective systems, are also examined. Cutting-edge technologies, including 3D printing, AI-driven formulation optimization, and smart polymers, are highlighted for their potential to revolutionize bioavailability enhancement. Regulatory considerations and challenges associated with these innovative techniques are addressed, with a focus on safety, efficacy, and scalability. Future perspectives on personalized medicine and integration of nanotechnology, AI, and biotechnology suggest a promising path for overcoming the limitations of oral drug bioavailability. This review provides a comprehensive overview of current advancements and emerging trends in bioavailability enhancement techniques, offering insights into the future of oral drug development.

**KEYWORDS:** oral bioavailability, drug delivery systems, nanotechnology, lipid-based formulations, prodrugs, 3D printing.

## INTRODUCTION

Oral drug bioavailability enhancement is a critical area of research in pharmaceuticals, as it directly impacts the efficacy and safety of medications. Poor bioavailability can lead to reduced therapeutic effectiveness, increased dosing requirements, and higher costs. Recent innovations have focused on improving drug solubility, dissolution rates, and absorption, leveraging advanced formulation technologies and delivery systems.

Techniques for enhancing oral drug bioavailability include solid dispersion and size reduction, which improve solubility and dissolution rates by dispersing drugs in a solid matrix or reducing particle size to the nanoscale. Lipid-based formulations, such as liposomes and self-emulsifying drug delivery systems (SEDDS), enhance the bioavailability of hydrophobic drugs by improving solubility and facilitating absorption. Complexation and co-solvency methods are also used to form complexes with drugs or use co-solvents to enhance dissolution rates[1]. Emerging trends and technologies include oral mucosal drug delivery, which bypasses first-pass metabolism and enhances bioavailability by delivering drugs directly through the oral mucosa.

3D printed drug delivery systems allow for controlled release and improved absorption by tailoring drug release profiles to specific gastrointestinal environments. Crystal engineering and micronization modify drug crystal structures to enhance solubility and dissolution rates, improving bioavailability. These innovations not only enhance drug efficacy but also offer opportunities for product line extension and patenting, allowing pharmaceutical companies to expand their portfolios and bring drugs to market more efficiently[2].

## FACTORS INFLUENCING ORAL BIOAVAILABILITY

Oral bioavailability is influenced by a complex interplay of factors, including physicochemical properties of drugs, physiological barriers, and external influences such as food and first-pass metabolism.

### Physicochemical Properties of Drugs

The physicochemical properties of drugs significantly affect their oral bioavailability. Key factors include solubility, stability, molecular weight, and lipophilicity. Drugs with poor solubility struggle to dissolve in gastrointestinal fluids, leading to reduced absorption. Stability issues, such as chemical

| Access this article online | |
|---|---|
| **Website:** https://innovationaljournals.com/index.php/ip | **e-ISSN:** 2348-7275 |

degradation in the stomach, can also diminish bioavailability.

Molecular weight impacts diffusion rates across membranes, while lipophilicity affects the ability to cross lipid bilayers in the gut wall[3].

## Physiological Barriers

Physiological barriers play a crucial role in determining oral bioavailability. Intestinal permeability is a major factor, as drugs must cross the epithelial barrier to enter systemic circulation. Enzymatic degradation by gut enzymes and liver metabolism during first-pass effect can significantly reduce the amount of drug reaching the bloodstream. Additionally, efflux transporters like P-glycoprotein can pump drugs back into the gut lumen, further reducing absorption.

## Impact of Food, Gastric Emptying Rate, and First-Pass Metabolism

External factors such as food intake, gastric emptying rate, and first-pass metabolism also influence oral bioavailability. Food can alter drug absorption by changing gastric pH, affecting solubility, or interacting with transporters. A faster gastric emptying rate can reduce the time available for drug dissolution and absorption, while a slower rate may increase exposure to degradative enzymes. First-pass metabolism in the liver and gut wall can metabolize a significant portion of the drug before it reaches systemic circulation, reducing bioavailability[4].

## STRATEGIES FOR ENHANCING ORAL BIOAVAILABILITY

Enhancing oral bioavailability is crucial for improving the efficacy and safety of drugs, particularly those with poor solubility or permeability. Various strategies are employed to overcome these challenges, categorized into physicochemical, formulation-based, and biological/biopharmaceutical approaches.

## Physicochemical Approaches

Physicochemical strategies focus on modifying drug properties to enhance solubility and dissolution rates. Particle size reduction techniques, such as micronization and nanosizing, increase the surface area available for dissolution, thereby improving bioavailability. Salt formation and polymorph optimization involve creating alternative salt forms or cocrystals to enhance solubility. Amorphous solid dispersions are used to enhance dissolution rates by stabilizing drugs in a non-crystalline state, which often exhibits higher solubility than crystalline forms.

## Formulation-Based Approaches

Formulation-based strategies involve designing delivery systems that improve drug solubility, stability, and absorption. Lipid-based drug delivery systems (LBDDS), including self-emulsifying drug delivery systems (SEDDS) and nanoemulsions, enhance the solubility of hydrophobic drugs and facilitate absorption. Cyclodextrin complexation improves solubility and stability by forming inclusion complexes with drugs. Nanotechnology-based carriers, such as nanoparticles, liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), offer targeted delivery and improved bioavailability.

## Biological and Biopharmaceutical Approaches

Biological and biopharmaceutical strategies aim to overcome physiological barriers and enhance drug absorption. Enzyme inhibitors and permeability enhancers are used to overcome first-pass metabolism and intestinal efflux, ensuring more drug reaches systemic circulation. Prodrug design involves modifying drugs to enhance solubility and stability, improving absorption and reducing presystemic metabolism. Gastroretentive and mucoadhesive drug delivery systems prolong drug residence time in the gastrointestinal tract, allowing for sustained release and improved absorption[5].

## CUTTING-EDGE TECHNOLOGIES IN BIOAVAILABILITY ENHANCEMENT

Recent advancements in bioavailability enhancement involve innovative technologies that tailor drug delivery to specific needs, improving efficacy and reducing side effects. Key technologies include 3D printing, artificial intelligence (AI), and smart polymers.

## 3D Printing in Drug Formulation: Tailoring Drug Release Profiles

3D printing allows for the creation of customized tablets with tailored release profiles by manipulating internal geometries and materials. Techniques like fused deposition modeling (FDM) and selective laser sintering (SLS) enable the production of tablets with controlled release profiles, such as immediate, sustained, or delayed release. For instance, 3D printed tablets can be designed to provide constant, increasing, or decreasing drug release rates based on the internal architecture of the

tablet. This technology facilitates personalized medicine by allowing for the combination of multiple drugs and dosages into a single formulation[6].

### Artificial Intelligence (AI) in Drug Formulation Optimization: Predictive Modeling of Bioavailability

AI plays a crucial role in optimizing drug formulations by predicting bioavailability through machine learning algorithms. These models analyze large datasets of drug properties, formulation parameters, and biological responses to predict optimal formulations that enhance bioavailability. AI can simulate various scenarios, reducing the need for extensive experimental trials and accelerating the development of effective formulations.

### Smart Polymers and Stimuli-Responsive Drug Delivery Systems: Targeted and Controlled Release Approaches

Smart polymers are designed to respond to specific stimuli, such as pH, temperature, or light, allowing for targeted and controlled drug release. These polymers can encapsulate drugs in responsive matrices that release the active ingredients only when needed, improving bioavailability and reducing side effects. Stimuli-responsive drug delivery systems enhance therapeutic efficacy by delivering drugs directly to the site of action, minimizing systemic exposure, and optimizing treatment outcomes[7].

## REGULATORY CONSIDERATIONS AND CHALLENGES

The development and implementation of novel bioavailability enhancement methods face several regulatory considerations and challenges. These include safety and efficacy concerns, regulatory guidelines, and issues related to stability, scalability, and cost-effectiveness.

### Safety and Efficacy Concerns of Novel Bioavailability Enhancement Methods

New bioavailability enhancement technologies, such as nanotechnology and advanced formulation techniques, raise safety and efficacy concerns. For instance, nanoparticles may pose risks due to their small size and potential for systemic distribution, necessitating thorough toxicological evaluations. Additionally, formulations like self-emulsifying drug delivery systems (SEDDS) and amorphous solid dispersions (ASDs) require rigorous testing to ensure they do not alter the drug's pharmacokinetic profile in unintended ways.

### Regulatory Guidelines for Bioavailability-Enhancing Formulations (FDA, EMA Perspectives)

Regulatory agencies like the FDA and EMA provide guidelines for the approval of bioavailability-enhancing formulations. For example, the FDA has issued guidance on the evaluation of bioequivalence for formulations involving complexation with cyclodextrins, emphasizing the need for in vitro permeation studies to support bioequivalence claims. The EMA also requires comprehensive data on the safety and efficacy of novel formulations, including detailed pharmacokinetic studies to ensure that enhanced bioavailability does not compromise drug safety.

### Stability, Scalability, and Cost-Effectiveness of New Technologies

New technologies must demonstrate stability over time, scalability for large-scale production, and cost-effectiveness to be viable. Spray-dried dispersions and melt-extruded solid dispersions are examples of scalable technologies that improve bioavailability while addressing manufacturing and stability challenges. However, the high development costs and complexity of some novel formulations can limit their adoption, especially for generic drugs where profit margins are lower. Regulatory frameworks often encourage innovation by providing pathways for expedited approval of formulations that significantly improve bioavailability, but these must balance innovation with safety and cost considerations[8].

## FUTURE PERSPECTIVES

Emerging trends and next-generation bioavailability enhancement techniques are poised to revolutionize drug delivery by leveraging cutting-edge technologies and personalized approaches.

**Emerging Trends and Next-Generation Bioavailability Enhancement Techniques: Recent** advancements include the integration of nanotechnology, which enables targeted drug delivery through nanoparticles and nanostructured lipid carriers, improving solubility and absorption of poorly soluble drugs. Additionally, techniques like

hot-melt extrusion and solid dispersion are gaining prominence due to their ability to enhance solubility and bioavailability. The use of lipid-based formulations is also on the rise, as they offer advantages in mitigating food effects and enhancing solubilization of hydrophobic compounds.

**Potential Role of Personalized Medicine in Optimizing Drug Absorption:** Personalized medicine holds significant potential in optimizing drug absorption by tailoring formulations to individual patient needs. This involves using genetic data and physiological characteristics to predict optimal dosing regimens and bioavailability-enhancing strategies. For instance, genetic variations affecting drug metabolism can guide the selection of formulations that bypass first-pass metabolism or enhance intestinal absorption.

**Integration of Nanotechnology, AI, and Biotechnology for Improved Drug Delivery:** The integration of nanotechnology, artificial intelligence (AI), and biotechnology is expected to play a pivotal role in future drug delivery systems. Nanotechnology provides platforms for targeted delivery and enhanced solubility, while AI can predict optimal formulations and dosing strategies based on patient-specific data[9]. Biotechnology contributes by enabling the development of novel drug delivery systems, such as gene-edited cells for targeted therapy. This multidisciplinary approach promises to significantly improve drug efficacy and safety by optimizing bioavailability and minimizing side effects.

## CONCLUSION

Recent advancements in oral drug bioavailability enhancement have led to significant improvements in drug delivery and therapeutic outcomes. Strategies such as physicochemical modifications, formulation-based approaches, and biopharmaceutical interventions have proven effective in overcoming the barriers to absorption. Cutting-edge technologies, including nanotechnology, AI-driven formulations, and 3D printing, show great potential for further enhancing bioavailability. However, challenges related to safety, regulatory concerns, and scalability must be addressed. Future developments hold promises for more personalized and efficient oral drug therapies.

## REFERENCE

1. Fasinu, P., Pillay, V., Ndesendo, V. M., du Toit, L. C., & Choonara, Y. E. (2011). Diverse approaches for the enhancement of oral drug bioavailability. Biopharmaceutics & drug disposition, 32(4), 185-209.
2. Gomez-Orellana, I. (2005). Strategies to improve oral drug bioavailability. Expert opinion on drug delivery, 2(3), 419-433.
3. Heaney, R. P. (2001). Factors influencing the measurement of bioavailability, taking calcium as a model. The Journal of nutrition, 131(4), 1344S-1348S.
4. McLean, A. J., McNamara, P. J., DuSouich, P., Gibaldi, M., & Lalka, D. (1978). Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism. Clinical Pharmacology & Therapeutics, 24(1), 5-10.
5. Gomez-Orellana, I. (2005). Strategies to improve oral drug bioavailability. Expert opinion on drug delivery, 2(3), 419-433.
6. Patel, M. M. (2011). Cutting-edge technologies in colon-targeted drug delivery systems. Expert opinion on drug delivery, 8(10), 1247-1258.
7. Wells, C. M., Harris, M., Choi, L., Murali, V. P., Guerra, F. D., & Jennings, J. A. (2019). Stimuli-responsive drug release from smart polymers. Journal of functional biomaterials, 10(3), 34.
8. Shapiro, M. A., Swann, P. G., & Hartsough, M. (2007). Regulatory Considerations. Handbook of Therapeutic Antibodies, 277-300.
9. Choi, Y. H., & Han, H. K. (2018). Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. Journal of pharmaceutical investigation, 48(1), 43-60.